Prostate cancer is the most common cancer in the world Western countries and represents the second cause of death for oncological disease in men. While hormone-based therapy is usually effective initially, the majority of prostate cancer will develop hormonoresistance and often metastases, after which treatment options are limited. A chemotherapy including docetaxel has been shown to improve the overall survival and clinical benefit in these clinical conditions; however, as a chemotherapy regimen some adverse events are associated, there is controversy about the right time to initiate and the best duration's treatment. Additionally, age and comorbidities sometimes precludes the use of some antitumoral agents. According to this, new treatment options are needed for patients affected by castration resistant prostate cancer (CRPC) in order to improve the disease control without a detrimental effect in their quality of life.
|Translated title of the contribution||Prostate cancer in the elderly: Which therapy?|
|Number of pages||6|
|Journal||Geriatric and Medical Intelligence|
|Publication status||Published - 2010|
ASJC Scopus subject areas
- Geriatrics and Gerontology